- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, single-arm trial to investigate tepotinib in advanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION)
This study is looking at a new medicine called tepotinib for certain types of advanced lung cancer. It aims to see how well it shrinks tumours in people with specific changes in their cancer cells (METex14 skipping or MET amplification).
For: Lung CancerBelgium · France · Poland - Active not recruitingPHASE2
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
This study explored a new combination of medicines, tepotinib and osimertinib, for people with a specific type of advanced lung cancer. It looked at whether this combination could shrink tumours, was safe, and how the body handled the drugs after their initial treatment stopped working.
For: Non-small Cell Lung CancerUnited States · Belgium · China - Active not recruitingPHASE1
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
This study combines two drugs, tepotinib and pembrolizumab, for advanced non-small cell lung cancer. It explores if tepotinib can make immunotherapy like pembrolizumab more effective, especially for cancers that usually don't respond well to such treatments.
For: Advanced Cancer · Non Small Cell Lung CancerUnited Kingdom - RecruitingPHASE3
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
This study compares a new drug called tepotinib with standard treatments for advanced lung cancer. It's for people whose cancer has a specific change (MET Exon 14 mutation) and has already been treated. The aim is to see if tepotinib works better to stop the cancer from growing.
For: Advanced Non Small Cell Lung Cancer · MET Exon 14 MutationFrance